Current Status and Perspective of Immunotherapy for Head and Neck Squamous Cell Carcinoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 1430
Special Issue Editors
Interests: head and neck cancer; immunotherapy; targeted therapy
Interests: head and neck cancer (HNSCC); tumorimmunology; immunotherapy; clinical study HNSCC; platelets; platelet-driven cancer progression; toll like receptors and cancer
Special Issue Information
Dear Colleagues,
Head and neck squamous cell carcinoma (HNSCC) is the most frequent cancer of the head and neck.
Immune-checkpoint inhibitors have changed the outcome for some for some patients with recurrent or metastatic HNSCC (R/M HNSCC).
However, most patients with HNSCC present primary or secondary resistance under anti PD1/PD-1. A number of clinical trials have failed to demonstrate efficacy in both locally advanced diseases and in RM HNSCC.
Novel biomarkers and novel strategies for association are needed to increase the efficacy of immunotherapy for head and neck cancer patients, as locally advanced diseases or in the R/M setting.
Therefore, we are looking for manuscripts covering the current status in local diseases or R/M, as well as novel strategies for use immune-checkpoint inhibitors for HNSCC. This Special Issue welcomes the submission of reviews as well as original research articles.
Dr. Amaury Daste
Prof. Dr. Wollenberg Barbara
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- head and neck cancer
- immunotherapy
- molecular pathogenesis
- tumor biology
- head and neck squamous cell carcinoma
